Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069769 | 0.86 | HCRTR2 (0.49) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL17449243 | 0.80 | HCRTR1 (0.51) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL16025403 | 0.78 | HCRTR2 (0.50) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL27900612 | 0.78 | HCRTR2 (0.49) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL31707742 | 0.76 | HCRTR1 (0.51) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL1586788 | 0.76 | HCRTR1 (0.51) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL17761282 | 0.75 | HCRTR1 (0.47) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL17069766 | 0.74 | HCRTR2 (0.51) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL19604231 | 0.73 | HCRTR1 (0.47) | HCRTR2HCRTR1CYP1A2 | |
| SCHEMBL21894128 | 0.73 | HCRTR1 (0.43) | HCRTR2HCRTR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885CYP1A2 1353/4885 |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885CYP1A2 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.